Lomefloxacin ) is a new difluoroquinolone agent. It inhibited 90% of Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus mirabilis, Morganella morganii, Proteus vulgaris, Serratia marcescens, Salmonella spp., Shigella spp., Aeromonas spp., Yersinia spp., Haemophilus influenzae, and Neisseria gonorrhoeae at .2 ,ug/ml. Lomefloxacin inhibited 90% of Pseudomonas aeruginosa at 4 ,Ig/ml.
A number of extremely active quinolone antimicrobial agents have been synthesized in the past decade. These agents inhibit most members of the family Enterobacteriaceae, including many organisms resistant to beta-lactams and aminoglycosides (6) . Quinolones also have excellent activity against Pseudomonas aeruiginosa and some other nonfermenting gram-negative species. Recent efforts have been directed at the development of new quinolones with improved pharmacokinetic properties. Lomefloxacin, also referred to as SC-47111 or as [1-ethyl-6 ,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid hydrochloride], is a new quinolone that has been reported in preliminary studies to have good antimicrobial activity and improved pharmacokinetics (4) . The purpose of this study was to investigate the in vitro activity of lomefloxacin and to compare its activity with those of other quinolones. Klebsiella oxytocaa (20) Enterobacter aerogenes" (30) Enterobacter cloacae" b (30)
MATERIALS AND METHODS
Hafnia alvei'
Citrobacter freundii"ab (30) Citrobacter diversus (20) Proteus mirabilis (30) Continued on following page incubator at 37°C, lomefloxacin was removed by filtration through a filter (Millipore Corp., Bedford, Mass.). Bacterial cells were washed three times with prewarmed sterile urine and suspended in antibiotic-free urine. Bacterial counts were determined before and after lomefloxacin was removed by plating serial dilutions onto Mueller-Hinton agar. Thereafter, the number of CFU was determined every hour for 10 h. The postantibiotic effect was measured as described by Craig and Gudmundsson (3) as the difference in time required by test and control cultures to increase 1 log unit after the antimicrobial agent was removed.
RESULTS
The overall activity of lomefloxacin compared with those of other quinolone compounds is shown in Table 1 . The concentration of lomefloxacin which inhibited 50% of the members of the family Enterobacteriaceae was 0.5 ,ug/ml, with the exception of Providencia spp. The MIC for 90% (MIC90) of the Enterobacteriaceae was '1 jig/ml, except for Providencia spp., Proteus rettgeri, and Serratia marcescens. The MIC90 for Pseudomonas aeruginosa was 4 ,g/ml, and for the other Pseudomonas spp. it was 8 to 16 ,ug/ml, while the MIC90 for Acinetobacter was 4 ,ug/ml.
Lomefloxacin inhibited Haemophilus influenzae at 0.12 ,ug/ml, Branhamella catarrhalis at 0.25 ,ug/ml, and Neisseria gonorrhoeae at <0.12 ,ug/ml. This included isolates of Haemophilus influenzae and Neisseria gonorrhoeae that were resistant to ampicillin and erythromycin (data not shown). Lomefloxacin inhibited the small number of Legionella pneumophila tested at 0.25 p.g/ml. Although Table 1 does not show the data, included among the isolates were organisms resistant to cephalosporins such as ceftazidime, penicillins such as piperacillin, aminoglycosides, and organisms resistant to imipenem. All five isolates of Enterobacter cloacae resistant to cefotaxime and ceftazidime were inhibited by 0.5 ,ug of lomefloxacin per ml. Serratia marcescens, Klebsiella pneumoniae, and Acinetobacter anitratus resistant to gentamicin were inhibited by 2 ,ug of lomefloxacin per ml; and isolates of Pseudomonas aeruginosa, including 10 isolates that were resistant to piperacillin, gentamicin, and imipenem, were inhibited by 4 p.g of lomefloxacin per ml. Those Salmonella spp.; including the small number of Salmonella typhi, resistant to chloramphenicol and trimethoprim-sulfamethoxazole were inhibited by .0.25 ,ug of lomefloxacin per ml.
Lomefloxacin and norfloxacin had similar MIC90s for Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter diversus, and Morganella morganii; but norfloxacin was twofold more active against Citrobacter freundii, Proteus vulgaris, Proteus rettgeri, Providencia stuartii, Serratia marcescens, Aeromonas spp., Yersinia spp., Salmonella spp., and Shigella spp. Lomefloxacin was more active than norfloxacin against Pseudomonas spp. In general, the activity of enoxacin paralleled that of norfloxacin for the Enterobacteriaceae. Ciprofloxacin was the most active compound, being 4-to 16-fold more active than lomefloxacin, depending on the species.
The activity of lomefloxacin against gram-positive and anaerobic species is shown in ,ug/ml. The MIC%0s for enterococci were 16 pLg/ml, and those for Streptococcus pneumoniae and Listeria monocytogenes were 8 p,g/ml. The activity of lomefloxacin against staphylococci was comparable to those of norfloxacin and enoxacin, but it was twofold more active than norfloxacin and enoxacin against other gram-positive species. Ciprofloxacin and ofloxacin were fourfold more active against the staphylococci and four-to eightfold more active against the streptococcal and enterococcal species. Lomefloxacin had minimal activity against Bacteroides fragilis (MIC90, 64 ,ug/ml), and
MIC90s for Clostridium species were also high.
Effect of pH, magnesium concentration, anaerobiosis, and inoculum size on activity. The effect of pH and Mg2" concentration on the activity of lomefloxacin was determined since it has been noted that both pH and divalent cations can alter the activity of quinolones (1) . when sterile urine was used as medium were determined for two isolates each of the species listed in Table 3 . For example, the MICs in urine for Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were 4, 4, and 8 1g/ml, respectively, which were identical to the MICs in Mueller-Hinton broth at pH 5.5 and 9 mM Mg2+. The MICs of lomefloxacin determined under anaerobic conditions were identical or within twofold of the aerobically determined MICs for five isolates each of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Providencia stuartii, and Salmonella enteritidis.
The effect of inoculum size on the MICs of lomefloxacin is shown in Table 4 . There was an increase of two-to eightfold in the MIC v at 107 CFU compared with the MIC at 105
CFU. There was only a two-or fourfold difference in MICs and MBCs (Table 5) for Escherichia coli, Klebsiella pneumoniae, and Serratia marcescens and eightfold for Pseudomonas aeruginosa.
The activity of lomefloxacin was determined against Escherichia coli JF568 (obtained from H. Nikaido) and its two mutants lacking outer membrane proteins (OMPs), OMPF and OMPC. The MIC against the isogenic strain which lacked OMPF was twofold higher than those against the OMPF+ OMPC+ and the OMPF+ OMPC-strains.
Development of resistance to lomefloxacin. An Escherichia coli transferred daily for 15 days in lomefloxacin had an increase in MIC from 0.12 to 1 pLg/ml. The MIC for a methicillin-resistant Staphylococcus aureus that was transferred similarly increased from 0.5 to 2 ,ug/ml, and the MIC for Pseudomonas aeruginosa increased from 1 to 8 ,ug/ml.
The MIC increases remained stable after three daily passages on drug-free medium. The MICs of norfloxacin, ofloxacin, and enoxacin increased a similar fold for the three isolates. The frequency of a spontaneous, single-step eightfold increase in the MIC of lomefloxacin for two isolates each of Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Serratia marcescens, and Pseudomonas aeruginosa was <10-'°.
The activities of lomefloxacin against organisms which were selected for resistance to other quinolones by repeated transfer or which had developed resistance to quinolones during therapy are shown in Table 6 . The MICs for the quinolone-resistant isolates were, in all cases, increased for lomefloxacin, similar to increases seen with the selecting agent. Postantibiotic effect of lomefloxacin. Quinolones have been shown to produce a postantimicrobial effect on both grampositive and -negative bacteria (2) . The postantibiotic effect of lomefloxacin was determined in urine for an Escherichia coli for which the MIC of lomefloxacin was 0.12 ,ug/ml and for a mutant E. coli selected by passage in the drug for which the MIC was 1 ,ug/ml. The postantibiotic effect after exposure to 200 ,ug/ml for 2 h was 3 h for both isolates. Exposure of the Escherichia coli to 200 p.g of lomefloxacin per ml produced a 3.5-log-unit decrease in CFU. When Escherichia coli was exposed to lomefloxacin at four and eight times the MIC, as determined in urine, there was a 3-log-unit decrease in CFU at 2 h and regrowth was not seen over the following 24 h. DISCUSSION Lomefloxacin, a new quinolone antimicrobial agent, has a broad spectrum of antibacterial activity against gram-negative bacteria. The overall in vitro activity of lomefloxacin is similar to those of norfloxacin and enoxacin against species such as Escherichia coli, Klebsiella spp., and Enterobacter spp. but is twofold less active against Proteus spp., Providencia spp., and Serratia spp. In general, ofloxacin was twoto fourfold more active and ciprofloxacin was much more active, particularly against gram-positive species. The results of this study are similar to those of Hirose et al. (4) . In general, 90% of the members of the family Enterobacteriaceae, with the exception of some Proteus spp. and Providencia spp., were inhibited by .2 jig of lomefloxacin per ml. Lomefloxacin also inhibited 50% of the isolates of Pseudomonas aeruginosa, including isolates that were resistant to penicillins, cephalosporins, and aminoglycosides, at 2 ,ug/ml; and 90% were inhibited by 4 ,ugIml, a concentration well below that which is achievable in urine.
Like other quinolones of this type, lomefloxacin was less active at an acid pH than at neutral pH, and its activity was also lowered in the presence of Mg2+ concentrations similar to those found in urine. MICs in urine were similar to the MICs at pH 5.5 and 9 mM Mg2+. The frequency of spontaneous single-step resistance to lomefloxacin was low (<1010 CFU), but MICs were increased by serial passage of organisms in increasing concentrations of the drug. Although lomefloxacin inhibited organisms that were resistant to cephalosporins, penicillins, aminoglycosides, and even imipenem, MICs for isolates previously selected for resistance to other quinolones by serial passage or during clinical use of the drug were increased to the same degree as were those for the selecting agent.
Lomefloxacin inhibited staphylococci, including methicil- 
